Free Cash FlowNot reportedfor the trailing 12 months
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USDFYE December
This page shows Oragenics (OGEN) financial statements, including the
income statement, balance sheet, cash flow statement, and key financial ratios.
View 15 years of annual fundamentals and quarterly data, with year-over-year
growth rates and compound annual growth rates (CAGR).
All figures are derived from SEC filings (10-K and 10-Q reports).
Rhea AIOGENFY2025
Oragenics operates as a development-stage company where research spending and operating losses are funded primarily through external capital.
In FY2025, operating cash flow of -$9.2M nearly matched the operating loss of -$9.4M, indicating that reported losses were accompanied by cash consumption rather than driven mainly by non-cash charges.
The business was not yet commercially scaled in FY2021-FY2023: R&D exceeded revenue in each reported year, reaching $15.5M against $38K in FY2023. The larger research line and persistent operating losses indicate spending ahead of a revenue base, rather than costs supported by established sales.
External financing appears to be the balance-sheet mechanism: financing cash flow was $16.8M in FY2025 while equity was $8.3M, after negative equity in FY2024. Assets rebounded from $1.5M in FY2024 to $10.1M in FY2025, so the latest balance-sheet improvement is not evidence of operating self-funding; the debt-to-equity ratio was just 0.2x.
Financial Health Signals
Financial health score not available
Oragenics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Interest CoverageAt Risk
N/A
Oragenics reported an operating loss of $9.4M against $786K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Oragenics earned -$4.56 per diluted share (EPS) in fiscal year 2025.
Revenue
Not reported for fiscal year 2025.
EBITDA
Not reported for fiscal year 2025.
Net Income
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cash & Debt
$4.4M
YoY+408.7%
5Y CAGR-24.2%
10Y CAGR-1.4%
Oragenics held $4.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Shares Outstanding
4M
Oragenics had 4M shares outstanding in fiscal year 2025.
Free Cash Flow
Not reported for fiscal year 2025.
Dividends Per Share
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
R&D Spending
$2.4M
YoY-41.8%
5Y CAGR-35.9%
10Y CAGR-12.1%
Oragenics invested $2.4M in research and development in fiscal year 2025. This represents a decrease of 41.8% from the prior year.
Share Buybacks
Not reported for fiscal year 2025.
Capital Expenditures
Not reported for fiscal year 2025.
OGEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
OGEN annual income statement
OGEN quarterly income statement
Metric
TTM
FY25
FY24
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
FY14
FY13
FY12
FY11
Revenue
N/A
N/A
N/A
$38K-71.4%
$132K+51.2%
$87K
N/A
N/A
N/A
$0
$0
$0-100.0%
$940K-8.9%
$1.0M-22.5%
$1.3M-7.8%
$1.4M
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
$0
$0
$0-100.0%
$370K+7.6%
$343K-60.9%
$878K+23.1%
$714K
Gross Profit
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
$0
$0
$0-100.0%
$570K-17.2%
$689K+52.0%
$453K-38.0%
$731K
R&D Expenses
N/A
$2.4M-41.8%
$4.1M-73.4%
$15.5M+53.8%
$10.1M-4.9%
$10.6M-52.1%
$22.1M+82.4%
$12.1M+103.0%
$6.0M+68.7%
$3.5M-25.6%
$4.8M-45.6%
$8.7M+184.9%
$3.1M-67.3%
$9.4M+19.1%
$7.9M+221.0%
$2.4M
SG&A Expenses
N/A
$7.0M+8.2%
$6.4M+18.2%
$5.5M+21.7%
$4.5M-15.0%
$5.3M+16.3%
$4.5M+20.7%
$3.8M-6.6%
$4.0M+26.5%
$3.2M-16.1%
$3.8M+6.9%
$3.5M+6.7%
$3.3M-55.9%
$7.5M+50.1%
$5.0M-10.7%
$5.6M
Operating Income
N/A
-$9.4M
N/A
-$20.9M-45.0%
-$14.4M+8.6%
-$15.8M+40.8%
-$26.6M-67.8%
-$15.9M-58.9%
-$10.0M-48.8%
-$6.7M+21.4%
-$8.5M+27.5%
-$11.8M-102.5%
-$5.8M+64.1%
-$16.2M-30.4%
-$12.4M
N/A
Interest Expense
N/A
$786K+2534.9%
$30K-2.5%
$31K+102.5%
$15K-4.1%
$16K+47.5%
$11K+46.4%
$7K+26.2%
$6K-97.3%
$216K+5155.8%
$4K-94.6%
$77K+1802.4%
$4K-77.0%
$18K-97.3%
$656K+97.2%
$332K
Income Tax
N/A
-$137K
N/A
N/A
N/A
N/A
N/A
N/A
$0
$0
$0
$0
$0
$0
N/A
N/A
Net Income
N/A
N/A
N/A
-$20.7M-44.6%
-$14.3M+9.1%
-$15.7M+40.6%
-$26.4M-69.8%
-$15.6M-57.0%
-$9.9M-47.3%
-$6.7M+4.0%
-$7.0M+40.1%
-$11.7M-102.3%
-$5.8M+64.0%
-$16.1M-22.8%
-$13.1M
N/A
EPS (Diluted)
-$2.44
-$4.56
-$47.88
-$9.18-29.1%
-$7.11
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Metric
Q2'26
Q1'26
Q4'25
Q3'25
Q2'25
Q1'25
Q4'24
Q3'24
R&D Expenses
$1.2M+82.3%
$645K
N/A
$931K+107.0%
$450K+31.7%
$342K
N/A
$879K
SG&A Expenses
$1.4M-12.1%
$1.6M
N/A
$2.2M+73.4%
$1.3M-24.9%
$1.7M
N/A
$1.6M
Operating Income
-$2.6M-14.9%
-$2.3M
N/A
-$3.1M-82.2%
-$1.7M+15.4%
-$2.0M
N/A
-$2.4M
Interest Expense
$414-88.9%
$4K
N/A
$7K-98.8%
$572K+187.4%
$199K
N/A
$10K
Income Tax
-$46K-105.0%
-$23K
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-$2.5M-14.9%
-$2.2M
N/A
-$3.1M-35.0%
-$2.3M-2.5%
-$2.2M
N/A
-$2.5M
EPS (Diluted)
-$0.57-11.8%
-$0.51-185.0%
$0.60+130.6%
-$1.96
-$3.10
-$3.65-3218.2%
-$0.11+99.0%
-$11.32
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OGEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
OGEN annual balance sheet
OGEN quarterly balance sheet
Metric
FY25
FY24
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
FY14
FY13
FY12
FY11
Total Assets
$10.1M+583.7%
$1.5M-70.4%
$5.0M-66.3%
$14.8M-47.7%
$28.2M+51.1%
$18.7M-5.4%
$19.8M-10.4%
$22.0M+205.6%
$7.2M+67.4%
$4.3M-25.4%
$5.8M-48.1%
$11.1M-33.9%
$16.8M+60.5%
$10.5M+727.8%
$1.3M
Current Assets
$10.1M+583.7%
$1.5M-61.9%
$3.9M-72.9%
$14.3M-48.4%
$27.7M+54.1%
$18.0M-4.5%
$18.8M-14.1%
$21.9M+204.9%
$7.2M+70.4%
$4.2M-25.1%
$5.6M-48.9%
$11.0M-34.4%
$16.8M+61.5%
$10.4M+830.3%
$1.1M
Cash & Equivalents
$4.4M+408.7%
$865K-75.2%
$3.5M-69.5%
$11.4M-58.1%
$27.3M+54.6%
$17.6M-3.4%
$18.3M-9.6%
$20.2M+227.7%
$6.2M+51.1%
$4.1M-19.7%
$5.1M-51.4%
$10.4M-35.8%
$16.3M+64.0%
$9.9M+5679.7%
$172K
Inventory
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
$0-100.0%
$322K-26.8%
$439K+52.3%
$288K+132.2%
$124K-73.9%
$476K
Accounts Receivable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
$0-100.0%
$21K+35.3%
$16K-75.8%
$64K-7.7%
$70K-24.7%
$93K
Total Liabilities
$1.8M+6.1%
$1.7M-6.3%
$1.8M+2.8%
$1.7M+0.2%
$1.7M-5.0%
$1.8M-27.2%
$2.5M+115.9%
$1.2M+29.9%
$899K-33.1%
$1.3M+28.3%
$1.0M+31.5%
$796K-19.8%
$993K-21.0%
$1.3M-86.7%
$9.4M
Current Liabilities
N/A
N/A
$1.8M+12.6%
$1.6M+10.4%
$1.4M+7.7%
$1.3M-27.5%
$1.9M+58.5%
$1.2M+29.9%
$899K-33.1%
$1.3M+28.3%
$1.0M+31.5%
$796K-19.8%
$993K-21.0%
$1.3M-86.7%
$9.4M
Total Equity
$8.3M+4008.4%
-$212K-106.7%
$3.2M-75.6%
$13.0M-50.9%
$26.5M+57.2%
$16.8M-2.2%
$17.2M-17.5%
$20.9M+230.6%
$6.3M+113.0%
$3.0M-37.3%
$4.7M-54.2%
$10.3M-34.7%
$15.8M+71.6%
$9.2M+212.9%
-$8.2M
Retained Earnings
-$226.6M-4.5%
-$216.8M-5.1%
-$206.2M-11.1%
-$185.6M-8.3%
-$171.3M-10.9%
-$154.4M-21.3%
-$127.4M-14.3%
-$111.4M-9.8%
-$101.4M-7.1%
-$94.7M-8.0%
-$87.7M-15.4%
-$75.9M-8.3%
-$70.2M-29.7%
-$54.1M-31.9%
-$41.0M
Metric
Q2'26
Q1'26
Q4'25
Q3'25
Q2'25
Q1'25
Q4'24
Q3'24
Total Assets
$5.5M-26.7%
$7.5M-25.6%
$10.1M-20.8%
$12.7M+493.8%
$2.1M-44.7%
$3.9M+162.8%
$1.5M-71.7%
$5.2M
Current Assets
$5.5M-26.7%
$7.5M-25.6%
$10.1M-20.8%
$12.7M+493.8%
$2.1M-44.7%
$3.9M+162.8%
$1.5M-64.2%
$4.1M
Cash & Equivalents
$3.9M-36.7%
$6.1M+38.8%
$4.4M-61.4%
$11.4M+477.8%
$2.0M-42.3%
$3.4M+295.6%
$865K-72.5%
$3.1M
Total Liabilities
$1.8M+39.3%
$1.3M-26.8%
$1.8M-37.8%
$2.9M-32.7%
$4.3M+14.4%
$3.7M+121.5%
$1.7M-20.8%
$2.1M
Total Equity
$3.7M-40.6%
$6.2M-25.4%
$8.3M-15.8%
$9.8M+562.1%
-$2.1M-1645.3%
$138K+165.0%
-$212K-106.9%
$3.1M
Retained Earnings
-$231.4M-1.1%
-$228.8M-1.0%
-$226.6M-1.0%
-$224.3M-1.4%
-$221.3M-1.0%
-$219.0M-1.0%
-$216.8M-1.6%
-$213.4M
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Current Liabilities, Long-Term Debt.
OGEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
OGEN annual cash flow statement
OGEN quarterly cash flow statement
Metric
TTM
FY25
FY24
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
FY14
FY13
FY12
FY11
Operating Cash Flow
-$10.2M
-$9.2M
N/A
-$7.3M+52.1%
-$15.2M-13.1%
-$13.5M+20.5%
-$17.0M-30.3%
-$13.0M-43.3%
-$9.1M-42.7%
-$6.4M+10.1%
-$7.1M-36.3%
-$5.2M+6.6%
-$5.6M+17.8%
-$6.8M-29.8%
-$5.2M+5.1%
-$5.5M
Capital Expenditures
N/A
N/A
N/A
N/A
$128K+190.6%
$44K
N/A
$25K-79.8%
$125K
N/A
$27K-73.5%
$103K-7.4%
$111K+488.4%
$19K+69.5%
$11K
N/A
Free Cash Flow
N/A
N/A
N/A
N/A
-$15.4M-13.6%
-$13.5M
N/A
-$13.0M-41.6%
-$9.2M
N/A
-$7.1M-34.2%
-$5.3M+6.7%
-$5.7M+16.4%
-$6.8M-29.9%
-$5.2M
N/A
Investing Cash Flow
N/A
N/A
N/A
-$936K-710.5%
-$116K-163.3%
-$44K
N/A
-$25K+79.8%
-$125K
N/A
$1.7M+1754.7%
-$101K
N/A
N/A
-$11K
N/A
Financing Cash Flow
$12.1M
$16.8M+180.7%
$6.0M+2006.1%
$284K+157.4%
-$495K-102.1%
$23.1M+41.8%
$16.3M+47.1%
$11.1M-52.3%
$23.2M+175.1%
$8.4M+89.8%
$4.5M+2883.0%
-$160K
N/A
N/A
$15.0M+170.6%
$5.5M
Share Buybacks
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
$4K
Metric
Q2'26
Q1'26
Q4'25
Q3'25
Q2'25
Q1'25
Q4'24
Q3'24
Operating Cash Flow
-$2.2M+0.6%
-$2.2M+22.4%
-$2.8M+5.0%
-$3.0M-127.1%
-$1.3M+37.8%
-$2.1M-4.6%
-$2.0M-2.4%
-$2.0M
Investing Cash Flow
$0-100.0%
$4.0M
N/A
N/A
N/A
N/A
N/A
N/A
Financing Cash Flow
-$56K+39.0%
-$92K+45.4%
-$169K-101.4%
$12.4M+9436.8%
-$133K-102.8%
$4.7M+1889.6%
-$261K-106.9%
$3.8M
Not reported in any period shown, so not listed: Dividends Paid.
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
OGEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
OGEN annual financial ratios
OGEN quarterly financial ratios
Metric
FY25
FY24
FY23
FY22
FY21
FY20
FY19
FY18
FY17
FY16
FY15
FY14
FY13
FY12
FY11
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
60.7%-6.1pp
66.7%+32.7pp
34.0%-16.6pp
50.6%
Operating Margin
N/A
N/A
-55519.9%
-10964.6%
-18130.3%
N/A
N/A
N/A
N/A
N/A
N/A
-618.8%
-1570.4%
-933.5%
N/A
Net Margin
N/A
N/A
-54858.1%
-10864.0%
-18062.0%
N/A
N/A
N/A
N/A
N/A
N/A
-616.0%
-1556.7%
-982.9%
N/A
Return on Equity
N/A
N/A
-652.0%-542.1pp
-109.8%-50.5pp
-59.3%+97.6pp
-156.9%-66.6pp
-90.3%-42.9pp
-47.5%+59.1pp
-106.6%+129.9pp
-236.5%+11.1pp
-247.5%-191.5pp
-56.0%+45.4pp
-101.4%+40.3pp
-141.8%
N/A
Return on Assets
N/A
N/A
-415.9%-319.1pp
-96.8%-41.2pp
-55.6%+85.8pp
-141.5%-62.7pp
-78.8%-33.8pp
-45.0%+48.3pp
-93.3%+69.4pp
-162.8%+39.9pp
-202.7%-150.7pp
-52.0%+43.5pp
-95.5%+29.3pp
-124.8%
N/A
Current Ratio
N/A
N/A
2.15-6.8x
8.95-10.2x
19.17+5.8x
13.40+3.2x
10.18-8.6x
18.79+10.8x
8.01+4.9x
3.14-2.2x
5.38-8.5x
13.84-3.1x
16.93+8.6x
8.28+8.2x
0.12
Debt-to-Equity
0.22
N/A
0.57+0.4x
0.13+0.1x
0.070.0x
0.110.0x
0.15+0.1x
0.06-0.1x
0.14-0.3x
0.45+0.2x
0.22+0.1x
0.080.0x
0.06-0.1x
0.14
N/A
FCF Margin
N/A
N/A
N/A
-11675.7%
-15535.8%
N/A
N/A
N/A
N/A
N/A
N/A
-603.2%
-657.2%
-392.2%
N/A
Metric
Q2'26
Q1'26
Q4'25
Q3'25
Q2'25
Q1'25
Q4'24
Q3'24
Return on Equity
-68.9%-33.3pp
-35.6%
N/A
-31.2%
N/A
-1610.2%
N/A
-80.0%
Return on Assets
-46.0%-16.6pp
-29.4%
N/A
-24.1%+82.0pp
-106.2%-48.9pp
-57.3%
N/A
-47.3%
Debt-to-Equity
0.50+0.3x
0.210.0x
0.22-0.1x
0.29
N/A
27.10
N/A
0.69
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Current Ratio, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Oragenics (OGEN) reported diluted earnings per share of -$4.56 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Oragenics's operating cash flow?
Oragenics (OGEN) recorded an outflow of $9.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Oragenics's total assets?
Oragenics (OGEN) had $10.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Oragenics spend on research and development?
Oragenics (OGEN) invested $2.4M in research and development during fiscal year 2025.
How many shares does Oragenics have outstanding?
Oragenics (OGEN) had 4M shares outstanding as of fiscal year 2025.
What is Oragenics's debt-to-equity ratio?
Oragenics (OGEN) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
How does Oragenics's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Oragenics (OGEN) held $8.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.2M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Can Oragenics cover its interest payments?
Oragenics (OGEN) reported an operating loss of $9.4M against $786K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
